As a novel treatment option for HF, sacubitril/valsartan showed a remarkable reduction in HF hospitalization (21%) and all‐cause mortality (16%) in the prospective comparison of angiotensin receptor neprilysin inhibitor with an angiotensin‐converting enzyme inhibitor to determine impact on global mortality and morbidity in HF (PARADIGM‐HF) trial.4 Here, ACE is linked to hydrops fetalis.